CPT® Code 81227

CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)

Molecular genetic testing is a critical procedure that focuses on identifying specific mutations within the CYP2C9 gene, which is located on chromosome 10. This gene encodes for the cytochrome P450, family 2, subfamily C, polypeptide 9, a complex protein that plays a vital role in the metabolism of various xenobiotics—substances that are foreign to the body, including drugs and toxins. The cytochrome P450 enzymes are essential for the bioactivation and synthesis of numerous biological compounds, such as cholesterol, steroids, and other lipids. Within the CYP2C9 gene, at least 50 single nucleotide polymorphisms (SNPs) have been identified in coding regions, which are linked to decreased enzyme activity. These genetic variations can lead to adverse drug reactions, often due to unexpected alterations in enzymatic function caused by polymorphisms. Notably, the common variants *2 and *3 are associated with a reduced capacity to metabolize warfarin, a commonly prescribed anticoagulant. Patients with these mutations typically require lower doses of warfarin to achieve therapeutic effects and are at a heightened risk for bleeding complications. Additionally, low-frequency variants such as *5 and *6 have been observed predominantly in African-American populations, with *5 associated with decreased enzyme activity and *6 linked to a complete lack of activity. Genetic testing for CYP2C9 mutations is particularly important for individuals undergoing specific drug therapies, such as those involving warfarin and phenytoin, as it helps identify genetic factors that may alter drug metabolism, potentially leading to toxicity even at standard therapeutic dosages.